Abstract: Methods and systems of applying physical stimuli to tissue are disclosed. The methods can include reducing or suppressing pancreatitis in a subject by administering a low magnitude, high frequency mechanical signal on a period basis and for a time sufficient to reduce or suppress pancreatitis. The methods can include enhancing healing of damaged tissue in a subject by administering to the subject a low magnitude, high frequency mechanical signal on a periodic basis and for a time sufficient to treat the damaged tissue. The systems can include a device for generating a low magnitude, high frequency physical signal and a platform for applying the low magnitude, high frequency physical signal to the subject for a predetermined time.

Abstract: A retractable half-body sauna device includes a main body, a retractable body, a first sliding member, and a second sliding member. The first sliding member is installed along inner surfaces of the bottom plate, the two side plates, or the bottom plate and the two side plates of the main body. The second sliding member is installed along outer surfaces of the bottom plate, the two side plates, or the bottom plate and the two side plates of the retractable body. The first and second sliding members are configured for engaging and sliding on each other so as to the retractable body is pulled partially out of and pushed partially into the main body, such that an inner space defined by the main body and the retractable body gets maximized and minimized, respectively.

Abstract: A lockable storage container and delivery device is provided that exposes the access port of liquid medicinal vials (such as for insulin) while maintaining identification, security, organization and inventory data access, for easy and documented administration of such medicine. The container has individual compartments for various types of medication, or variants of a similar medication (such as various types of insulin) in one convenient and secure container that provides optimal, efficient, cost-saving and safe delivery of medicine to patients.

Abstract: A frangible RFID tag includes a substrate having at least one weakened area, an RFID chip and an antenna. The RFID chip and the antenna are located on the substrate and the antenna is electrically connected to the RFID chip. The RFID tag also includes a plurality of adhesive areas applied to the underside of the substrate. The adhesive areas allow the RFID tag to be secured to an object. The adhesive areas may be spaced from one another to form at least one gap between the adhesive areas. The gap(s) may be located under the at least one weakened area.

Abstract: A vial access device, includes a body having a projecting annular skirt that is elastically deformable, for engaging a complementary shaped neck of a vial. A tubular spike extends coaxially within the annular skirt for introducing into the vial, and a tubular connector protrudes from the body on the side opposite to the annular skirt and in fluid communication with the tubular spike. The tubular spike and the annular skirt are arranged, respectively, within a first and a second part, distinct from each other, and of which the first part is permanently joined to the body and the second part is connectable to the first part through an irreversible coupling.

Abstract: A liquid-transfer adapter operatively interposable between an injector and a vial is provided. The adapter has an injector engaging portion configured for fluidly coupling to an injector and a vial coupling. The vial coupling includes a spike that has a spike axis and a tip portion configured for piercing a septum of a vial. The tip portion includes a plurality of facets that meet each other at one or more edges and at least one of the one or more edges is sloped with respect to the spike axis. The spike defines a channel extending therethrough in fluid communication with the injector engaging portion. A channel opening is defined in at least one of the facets and disposed without interrupting the edges.

Abstract: The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ?500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force.

Abstract: A bottle top for use with a baby bottle includes a ring bounding a mouth of the bottle top and being severed latitudinally between upper and lower portions. The upper portion has first and second lower contact faces. The lower portion has opposing first and second upper contact faces. The top includes a nipple coupled to the upper portion which moves between an open position, in which the nipple is away from the mouth and provides access to the mouth, and a closed position, in which the first upper and lower contact faces form a sealing engagement, the second upper and lower contact faces form another sealing engagement, and the nipple is in fluid communication with the mouth.

Abstract: A bottle top for use with a baby bottle includes a ring bounding a mouth of the bottle top and being severed latitudinally between upper and lower portions. The upper portion has first and second lower contact faces. The lower portion has opposing first and second upper contact faces. The top includes a nipple coupled to the upper portion which moves between an open position, in which the nipple is away from the mouth and provides access to the mouth, and a closed position, in which the first upper and lower contact faces form a sealing engagement, the second upper and lower contact faces form another sealing engagement, and the nipple is in fluid communication with the mouth.

Abstract: A nipple-shaped pacifier kit provides hypoallergenic molding powder, liquid silicone, a mixing bowl, a mixing tool, pacifier rings, and paper discs, each providing a slit for the insertion of the pacifier ring. The kit enables the adult user to create one or more pacifiers shaped like the human nipple.

Abstract: Apertured fibrous structures and more particularly apertured fibrous structures containing one or more fibrous elements, for example filaments, containing one or more fibrous element-forming materials and one or more active agents that are releasable from the fibrous element when exposed to conditions of intended use, and methods for making same.

Abstract: A cosmetic cleansing composition includes a) 0.1 to 30 wt. %, based on the total weight of the cleansing composition, of a surfactant selected from the group of anionic, non-ionic, and/or zwitterionic surfactants and mixtures thereof, b) at least one partially and/or non-neutralized, unbranched, saturated and/or unsaturated carboxylic acid with a chain length of 14 to 30 carbon atoms, and c) at least one non-ionic polymer of the formula (I) as set forth herein, where R represents a hydrogen atom or a methyl group and n represents a whole number value from 1,360 to 99,000. The cleansing composition has a mousse-like texture and excellent cleansing and care properties.

Abstract: Cleaning compositions including a non-ionic surfactant and a glycol ether are disclosed. These cleaning compositions are useful as liquid cleaners or de-greasers for animate surfaces, such as skin. The cleaning compositions provide improved cleaning and removal of soils without the use of certain VOCs.

Abstract: Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients.

Abstract: Provided is a composition including, as an active ingredient, at least one selected from the group consisting of amines, amides and polyols. The cosmetic composition has an effect of preventing aging and may be applied in various industrial fields, including cosmetics.

Abstract: The disclosure relates to topical compositions comprising a flavonoid compound and a vitamin B3 compound, and optionally a hydrolyzed silk protein or fragment thereof, which are useful for improving the health and appearance of aging skin An exemplary composition contains quercetin, hydrolyzed silk sericin and niacinamide.

Abstract: An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent.

Abstract: A powder-based cosmetic composition for application to skin is provided. The composition contains (a) one or more cosmetically acceptable particulates which are naturally hydrophobic or coated with a hydrophobic material; (b) at least one binder for the particulates of the powder-based cosmetic composition; and (c) a film-forming, oil-absorbing polymer having an affinity for sebum secreted from skin.

Abstract: Cosmetic or pharmaceutical compositions are disclosed herein for application to skin, hair and/or a nail of a subject, as well as methods utilizing same for administering hydrogen peroxide to skin, hair and/or a nail, and kits for applying same. The compositions comprise a hydrogen peroxide-producing enzyme, and a substrate of the hydrogen peroxide-producing enzyme. Further disclosed herein are cosmetic compositions and kits for lightening skin and/or hair, which further comprise a lignin peroxidase, as well as cosmetic methods utilizing same.

Abstract: The invention relates to oral and dental hygiene and cleaning agents for reducing restaining of teeth.

Abstract: Provided is a skin cleansing composition comprising the following components (A), (B), (C), (D), and (E): (A) 0.1 to 25 mass % of an ether oil which is in a liquid state at 25° C., (B) 0.003 to 1 mass % of a water-soluble polymer comprising acrylic acid or methacrylic acid as a constitutional unit, (C) 1 to 30 mass % of a hydrocarbon oil having a viscosity of 15 mPa·s or lower at 30° C., (D) 60 to 95 mass % of water, and (E) 0.49 mass % or less of a nonionic surfactant having an HLB of larger than 9, wherein the mass ratio of the component (B) to the component (A), (B)/(A) is from 0.0001 to 0.1, and the mass ratio between the component (A) and the component (C), (A)/((A)+(C)) is from 0.05 to 0.9.

Abstract: Provided are nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one acrylic non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition.

Abstract: A nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water are provided. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition.

Abstract: A nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one polyurethane non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water are provided. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition.

Abstract: The present invention relates to a cosmetic composition, especially a hair composition, comprising: —one or more associative nonionic polymers especially of polyurethane polyether type in an amount ranging from 2% to 60% by weight relative to the total weight of the composition, and —one or more carboxylate anionic surfactants. The invention also relates to a cosmetic treatment process using the said composition, especially a hair treatment process in particular for cleansing the hair and/or the scalp.

Abstract: The present invention relates to a cosmetic composition, especially a hair composition, comprising: —one or more associative nonionic polymers especially of polyurethane polyether type in an amount ranging from 2.5% to 60% by weight relative to the total weight of the composition, and —one or more amphoteric surfactants. The invention also relates to a cosmetic treatment process using the said composition, especially a hair treatment process in particular for cleansing the hair and/or the scalp.

Abstract: The present specification relates to a composition comprising processed ginseng extract and processed green tea extract. Such a composition results in having a synergistic effect due to mixing of each processed extract, and is thus capable of promoting the production of procollagen and inhibiting the expression of collagenase. In addition, the composition of the present specification promotes the expression of filaggrin and is thus capable of strengthening a skin barrier function and inducing the differentiation of skin keratinocytes. Therefore, the composition of the present specification is capable of improving the general condition of skin, and can be effectively used as an external preparation for skin for preventing or improving xeroderma, atopic dermatitis, contact dermatitis, psoriasis, or the like that is caused by the imperfection of epidermal differentiation.

Abstract: Magnetic drug-loaded polymeric particles are used in a transscleral drug delivery method. In the synthesis process of the aforementioned magnetic drug-loaded polymeric particles, therapeutic agents, along with a magnetic agent are encapsulated in a polymer. The aforementioned magnetic drug-loaded particles can be placed near the outer surface of the sclera, and then a magnetic field can be applied in front of the eye to pull these magnetic drug-loaded particles to the outer surface of the sclera, where these particles adhere to the outer surface of the sclera and thus, the orbital clearance of the particles is eliminated or reduced.

Abstract: A gel composition and method of manufacturing the same is discussed. The gel composition includes a plurality of chitosan spheres, an alkaline chitosan stabilizing agent, a chitosan decomposition enzyme and a drug. The chitosan spheres are formed by chitosan self-assembly. The alkaline chitosan stabilizing agent connects the chitosan spheres to form a gel body. The chitosan decomposition enzyme scatters in the gel body and decomposes the gel composition at a temperature of 20 to 40 degree Celsius. The drug scatters in the gel body.

Abstract: Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye.

Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Abstract: The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes.

Abstract: Various formulations of L-carnosine zinc (L-CAZ), and methods of using and administering such formulations to patients suffering from various diseases, disorders, or conditions are disclosed. In particular, low average particle size L-carnosine zinc is employed in various pharmaceutical compositions, including aqueous matrices and hydrogels.

Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.

Abstract: Provided is an ophthalmic nanoemulsion composition and a method for preparing the same which increases the solubility of cyclosporine as an active ingredient and improves the stability of the ophthalmic composition by mixing cyclosporine, a nonaqueous solvent, an emulsifier, and an aqueous solvent, and a method for preventing or treating dry eye syndrome using the same. The ophthalmic nanoemulsion composition is characterized by having an average particle size of 200 nm or less, preferably 100 nm or less, and having a very narrow particle distribution. Therefore, sterilizing filtration is available, stability is improved, and the composition has superior effect in clinical treatment of dry eye syndrome while minimizing foreign body sensation and visual disturbance, and thus the ophthalmic nanoemulsion composition of the present disclosure can be effectively used as an ophthalmic composition.

Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.

Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation.

Abstract: The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG.

Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (IOP) in the eye.

Abstract: A method of preparing drug agglomerates includes adding a drug powder to a first solvent to form a first solution, adding a second solvent to the first solution to form a second solution. The drug powder undergoes nucleation to form drug agglomerates. The drug agglomerates are isolated from the second solution.

Abstract: Described herein are systems and methods for transmucosal delivery of active agents. In some embodiments, a system may comprise one or more mucoadhesive devices configured for release of an active agent.

Abstract: The present invention includes compositions and methods of making a modified release pharmaceutical formulation and a method of preparation for the embedding of modified release multi-particulates into a polymeric or wax-like matrix. The modified release multi-particulates comprise an effective amount of a therapeutic compound having a known or desired drug-release profile. Modified release multi-particulates may include a polymeric coat or may be incorporated into particle or core material. The polymer matrix comprises a thermoplastic polymer or lipophilic carrier or a mixture thereof that softens or melts at elevated temperature and allows the distribution of the modified release multi-particulates in the polymer matrix during thermal processing. Formulation compounds and processing conditions are selected in a manner to preserve the controlled release characteristics and/or drug-protective properties of the original modified release multi-particulates.

Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release enteric soft capsules and matrices comprising fumarate esters are described.

Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.

Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.

Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: The invention concerns a method for preparing a double emulsion of a fat-soluble and hydrophobic active ingredient, which comprises the following steps: (a) Providing an aqueous solution of at least one whey protein; (b) Providing an aqueous solution of at least one anionic polysaccharide; (c) Subjecting the whey protein(s) to a denaturation treatment; (d) Hot-preparing an o/w emulsion of the active ingredient in the solution (c), then hot-preparing an (o/w)/w emulsion of the o/w emulsion in the solution (b), or (e) Preparing an w/w emulsion of the solutions (c) and (b), then hot-preparing an o/(w/w) emulsion of the active ingredient in the w/w emulsion. It also concerns the manufacturing of particles of said active ingredient from a thus prepared emulsion, and the obtained particles.

Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.